Last edition
News about "hematologic malignancies treatment"
Orca Bio Receives US FDA RMAT Designation for Orca-Q in Blood Cancers
Orca Bio receives US Food and Drug Administration (FDA) RMAT designation for Orca-Q in high-risk hematologic malignancies, backed by promising phase 1 data on survival and GVHD outcomes, with further results expected in 2026.
Hematologic Malignancies Treatment | 30/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members